and statin potency or lipophilicity. Results: 10,927 patients were classified as SU and PS-matched with SNU. SU showed a reduced risk of THA revision over a 15-year period (adjHR 0.76, 95% CI: ...

Patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who were taking cholesterol-lowering statin medications at the start of their cancer treatment had a 61% lower ...

As next steps, he recommended conducting laboratory studies to better understand how statins may influence cancer biology, as well as prospective clinical trials in which patients with CLL or SLL ...

Cholesterol-lowering statin drugs could be available to millions more patients in the UK, if new recommendations from health technology assessment (HTA) organisation NICE are implemented.

Introduction: Statins are prescribed to lower LDL-C in children with familial hypercholesterolemia and other dyslipidemias that accelerate atherosclerosis. Associations between statin use and type 2 ...

Patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who were taking cholesterol-lowering statin medications at the start of their cancer treatment had a 61% lower risk ...

Patients who used statins had a reduced risk for HCC, hepatic decompensation and fibrosis progression. Lipophilic statin use and longer duration of exposure were associated with even greater ...

The newer statins on the market have longer half-lives than the original statins. Alternative dosing schedules using once-, twice- or three-times a week or every-other-day dosing, have been ...